Compare Citius Pharmaceuticals Inc (CTXR) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Msci Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Msci Inc trades at $562 (market cap $40.84B). The key difference: Msci Inc is far larger — about 2041× Citius Pharmaceuticals Inc's market cap, and Msci Inc pays a 1.46% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MSCI | |
|---|---|---|
Market Cap | $20.01M | $40.84B |
Sector | Health | Financials |
52-Week High | $1.82 | $643.83 |
52-Week Low | $0.48 | $511.84 |
Enterprise Value | $16.23M | $47.00B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
MSCI trades at $563.01, down slightly (-0.01%) with a bearish technical signal. The company maintains strong fundamentals with $3.13B revenue, 40.73% net margin, and consistent earnings beats in three of the last four quarters. Recent acquisitions and strategic partnerships enhance its private markets platform. Analyst consensus remains strongly bullish with a $728.14 price target, representing 29% upside potential from current levels.
The outlook remains positive given MSCI's recurring revenue model, high client retention, and secular growth in private markets. Key risks include execution of recent acquisitions and market sensitivity to index performance. With strong profitability and Wall Street support, the stock presents a compelling long-term opportunity despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
